Cita APA

Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., & Hopp, M. (2017). Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study. Eur J Pain.

Citación estilo Chicago

Dupoiron, D., A. Stachowiak, O. Loewenstein, A. Ellery, W. Kremers, B. Bosse, y M. Hopp. "Long‐term Efficacy and Safety of Oxycodone‐naloxone Prolonged‐release Formulation (up to 180/90 Mg Daily) – Results of the Open‐label Extension Phase of a Phase III Multicenter, Multiple‐dose, Randomized, Controlled Study." Eur J Pain 2017.

Cita MLA

Dupoiron, D., et al. "Long‐term Efficacy and Safety of Oxycodone‐naloxone Prolonged‐release Formulation (up to 180/90 Mg Daily) – Results of the Open‐label Extension Phase of a Phase III Multicenter, Multiple‐dose, Randomized, Controlled Study." Eur J Pain 2017.